New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
This case study examines a patient who developed CSCC seven years after an initial kidney transplantation. Over the next 18 years the patient underwent multiple pharmacologic and surgical interventions for the treatment of multiple CSCCs, but the disease continued to progress. The patient was then treated with an anti-PDL1 immune checkpoint inhibitor (ICI), which stimulates immune system activity. Two months after initiation of the ICI, the patient experienced acute rejection of the transplanted kidney, which was then surgically removed. The patient remained on ICI therapy for another seven months and achieved a complete response. Four years later the patient underwent a kidney retransplantation and was monitored using AlloSure. 10.5 months following the retransplantation, the patient has had successful allograft function.
“Use of checkpoint inhibitors in transplant patients is new, and this is the first case of a re-transplanted patient. I am glad we had AlloSure to monitor the health of this patient,” said
“CareDx supports the continued innovation in transplant care, and continue to support centers like
Chief Marketing Officer
Source: CareDx, Inc.